The Change-Control Gap Between MDR and the AI Act
Predetermined change control plans reveal the specific reconciliation gap between MDR/IVDR certification and EU AI Act obligations for adaptive medical algorithms.
Predetermined change control plans reveal the specific reconciliation gap between MDR/IVDR certification and EU AI Act obligations for adaptive medical algorithms.
Computational pathology AI blurs device and biomarker regulation, but predetermined change control plans, not model freezing, may be the real fix.
EU and FDA are both building faster pathways for AI medical devices, but neither has defined what evidence should earn a device the fast lane.
Brussels pushed back the high-risk AI Act deadline for regulated medical devices, but MDR and IVDR certification bottlenecks did not move with it.
European MedTech is lobbying to revise how the EU AI Act and MDR/IVDR interact, and regulated buyers should build to the stricter combination now, not wait for the fix.
European regulators are revising the AI Act and MDR simultaneously, leaving life sciences compliance teams no stable baseline to build against.
The EU AI Act's delayed enforcement dates for medical device AI give sponsors more runway, but only if they use it to align MDR/IVDR and AI Act evidence now.
The EU's new Breakthrough Devices framework under MDR/IVDR speeds review timelines but leaves AI governance obligations fully intact.